Clinical Trial: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

---

Official Title: Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study

Brief Summary:

This is a multicenter, randomised phase II trial in patients with high risk GCT.

Primary objective:

• Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high risk' GCT as compared to standard care

Secondary objectives:

• Determine the relapse free survival
• Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT